US-based pharmaceutical company Pfizer has submitted a new drug application (NDA) for palbociclib to the US Food and Drug Administration (FDA).

The company is seeking approval for palbociclib, in combination with letrozole, to treat post-menopausal women with estrogen receptor positive (ER+) and human epidermal growth factor receptor two negative (HER2-) advanced breast cancer.

Pfizer Oncology president Garry Nicholson said: “Today’s submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer.”

Continue Reading

READ FULL ARTICLE Curated publisher From Pharmaceutical Technology